Revance Therapeutics (RVNC) Earnings Date, Estimates & Call Transcripts $3.65 0.00 (0.00%) As of 02/6/2025 Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Revance Therapeutics Earnings Summary Revance Therapeutics posted Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.37, which missed the consensus estimate of -$0.35 by $0.02. Quarterly revenue was reported to be $59.88 million, below the consensus estimate of $67.73 million. With a trailing EPS of -$1.93, Revance Therapeutics' earnings are expected to grow next year, from ($1.57) to ($1.08) per share. Upcoming Q4 Earnings DateAug. 6After Market ClosesEstimatedConsensus EPS (Nov. 7) -$0.35 Actual EPS (Nov. 7) -$0.37 Missed By -$0.02 Actual Revenue (Nov. 7) $59.88MQ3 2024 Earnings ResourcesQ3 2024 Earnings Report Press Release (8-K) Quarterly Report (10-Q)RVNC Upcoming EarningsRevance Therapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Powered by Get Revance Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revance Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRVNC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RVNC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Revance Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251-$0.49-$0.49-$0.49Q2 20251-$0.26-$0.26-$0.26Q3 20251-$0.26-$0.26-$0.26Q4 20251-$0.20-$0.20-$0.20 Revance Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------11/7/2024Q3 2024-$0.35-$0.37 -$0.02-$0.37$67.73M$59.88M8/8/2024Q2 2024-$0.48-$0.36+$0.12-$0.36$66.30M$65.39M5/9/2024Q1 2024-$0.66-$0.54+$0.12-$0.50$55.64M$51.94M2/28/2024Q4 2023-$0.79-$0.62+$0.17-$0.62$64.02M$69.80M11/8/2023Q3 2023-$1.02-$0.74+$0.28$0.15$58.49M$56.78M8/8/2023Q2 2023-$0.72-$0.80 -$0.08-$0.80$58.71M$58.13M Revance Therapeutics Earnings - Frequently Asked Questions When is Revance Therapeutics's earnings date? Revance Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on RVNC's earnings history. Did Revance Therapeutics beat their earnings estimates last quarter? In the previous quarter, Revance Therapeutics (NASDAQ:RVNC) missed the analysts' consensus estimate of ($0.35) by $0.02 with a reported earnings per share (EPS) of ($0.37). Learn more on analysts' earnings estimate vs. RVNC's actual earnings. How much revenue does Revance Therapeutics generate each year? Revance Therapeutics (NASDAQ:RVNC) has a recorded annual revenue of $234.04 million. How much profit does Revance Therapeutics generate each year? Revance Therapeutics (NASDAQ:RVNC) has a recorded net income of -$323.99 million. RVNC has generated -$1.93 earnings per share over the last four quarters. What is Revance Therapeutics's EPS forecast for next year? Revance Therapeutics's earnings are expected to grow from ($1.57) per share to ($1.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies Travere Therapeutics Earnings Structure Therapeutics Earnings Janux Therapeutics Earnings ARS Pharmaceuticals Earnings Adaptive Biotechnologies Earnings Vera Therapeutics Earnings Dyne Therapeutics Earnings ANI Pharmaceuticals Earnings Ocular Therapeutix Earnings Calliditas Therapeutics AB (publ) Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout? This page (NASDAQ:RVNC) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.